193 related articles for article (PubMed ID: 21654686)
21. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
Kerlikowske K; Molinaro AM; Gauthier ML; Berman HK; Waldman F; Bennington J; Sanchez H; Jimenez C; Stewart K; Chew K; Ljung BM; Tlsty TD
J Natl Cancer Inst; 2010 May; 102(9):627-37. PubMed ID: 20427430
[TBL] [Abstract][Full Text] [Related]
22. Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status.
Agosto-Arroyo E; Isayeva T; Wei S; Almeida JS; Harada S
Cancer Control; 2017 Jan; 24(1):102-110. PubMed ID: 28178722
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.
Allred DC; Clark GM; Molina R; Tandon AK; Schnitt SJ; Gilchrist KW; Osborne CK; Tormey DC; McGuire WL
Hum Pathol; 1992 Sep; 23(9):974-9. PubMed ID: 1355464
[TBL] [Abstract][Full Text] [Related]
24. Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers.
Schultz S; Bartsch H; Sotlar K; Petat-Dutter K; Bonin M; Kahlert S; Harbeck N; Vogel U; Seeger H; Fehm T; Neubauer HJ
BMC Med Genomics; 2018 Sep; 11(1):80. PubMed ID: 30236106
[TBL] [Abstract][Full Text] [Related]
25. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
[TBL] [Abstract][Full Text] [Related]
26. Abnormal expression of Nek2 and β-catenin in breast carcinoma: clinicopathological correlations.
Wang S; Li W; Lv S; Wang Y; Liu Z; Zhang J; Liu T; Niu Y
Histopathology; 2011 Oct; 59(4):631-42. PubMed ID: 22014044
[TBL] [Abstract][Full Text] [Related]
27. In search of triple-negative DCIS: tumor-type dependent model of breast cancer progression from DCIS to the invasive cancer.
Kurbel S
Tumour Biol; 2013 Feb; 34(1):1-7. PubMed ID: 23208673
[TBL] [Abstract][Full Text] [Related]
28. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ.
Boland GP; Butt IS; Prasad R; Knox WF; Bundred NJ
Br J Cancer; 2004 Jan; 90(2):423-9. PubMed ID: 14735188
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical COX-2 overexpression correlates with HER-2/neu overexpression in invasive breast carcinomas: a pilot study.
Çiriş IM; Bozkurt KK; Başpinar S; Kapucuoğlu FN
Pathol Res Pract; 2011 Mar; 207(3):182-7. PubMed ID: 21371829
[TBL] [Abstract][Full Text] [Related]
30. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
Park K; Han S; Kim HJ; Kim J; Shin E
Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
[TBL] [Abstract][Full Text] [Related]
31. Is there a low-grade precursor pathway in breast cancer?
King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
[TBL] [Abstract][Full Text] [Related]
32. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer.
Wang L; Hoque A; Luo RZ; Yuan J; Lu Z; Nishimoto A; Liu J; Sahin AA; Lippman SM; Bast RC; Yu Y
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3660-6. PubMed ID: 14506155
[TBL] [Abstract][Full Text] [Related]
33. Geometric characteristics of collagen have independent prognostic significance in breast ductal carcinoma in situ: an image analysis study.
Toss MS; Miligy IM; Gorringe KL; AlKawaz A; Mittal K; Aneja R; Ellis IO; Green AR; Roxanis I; Rakha EA
Mod Pathol; 2019 Oct; 32(10):1473-1485. PubMed ID: 31175326
[TBL] [Abstract][Full Text] [Related]
34. Breast ductal Carcinoma in situ associated with microinvasion induces immunological response and predicts ipsilateral invasive recurrence.
Chen XY; Thike AA; Koh VCY; Nasir NDM; Bay BH; Tan PH
Virchows Arch; 2021 Apr; 478(4):679-686. PubMed ID: 33140128
[TBL] [Abstract][Full Text] [Related]
35. Elevated expression of cyclooxygenase-2 in breast cancer and ductal carcinoma in situ has no correlation with established prognostic markers.
Ranger GS; Jewell A; Thomas V; Mokbel K
J Surg Oncol; 2004 Nov; 88(2):100-3. PubMed ID: 15499599
[TBL] [Abstract][Full Text] [Related]
36. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
[TBL] [Abstract][Full Text] [Related]
37. Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinoma in situ of the breast.
Van Bockstal M; Lambein K; Gevaert O; De Wever O; Praet M; Cocquyt V; Van den Broecke R; Braems G; Denys H; Libbrecht L
Histopathology; 2013 Oct; 63(4):520-33. PubMed ID: 23889174
[TBL] [Abstract][Full Text] [Related]
38. Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence.
Barnes N; Haywood P; Flint P; Knox WF; Bundred NJ
Br J Cancer; 2006 Jan; 94(2):253-8. PubMed ID: 16421596
[TBL] [Abstract][Full Text] [Related]
39. Evaluating the Risk of Upstaging HER2-Positive DCIS to Invasive Breast Cancer.
Mustafa RE; DeStefano LM; Bahng J; Yoon-Flannery K; Fisher CS; Zhang PJ; Tchou J; Czerniecki BJ; De La Cruz LM
Ann Surg Oncol; 2017 Oct; 24(10):2999-3003. PubMed ID: 28766212
[TBL] [Abstract][Full Text] [Related]
40. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes.
Goh CW; Wu J; Ding S; Lin C; Chen X; Huang O; Chen W; Li Y; Shen K; Zhu L
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1877-1886. PubMed ID: 31089799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
